查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1868840

按设备类型、药物类型、最终用户和分销管道分類的互联药物输送设备市场 - 全球预测 2025-2032

Connected Drug Delivery Devices Market by Device Type, Drug Type, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，互联药物输送设备市场将成长至 29.6819 亿美元，复合年增长率为 15.06%。

关键市场统计数据
基准年 2024 9.6622亿美元
预计年份：2025年 11.1068亿美元
预测年份 2032 2,968,190,000 美元
复合年增长率 (%) 15.06%

清楚阐述互联互通、以患者为中心的设计以及监管进步如何融合，从而变革药物输送设备和临床路径。

互联药物输送设备透过将感测器、软体和连接功能整合到传统输送平台中，正在重新定义治疗方法、患者和医疗保健系统之间的交互方式。随着临床路径转向分散式医疗和基于价值的治疗结果转变，能够收集依从性、剂量和情境生理数据的设备正变得对治疗方案至关重要。这项转变得益于低功耗电子技术、安全无线通讯协定的进步，以及围绕「软体即医疗设备」监管对话的日趋成熟，这些因素使得製造商能够从独立硬体转向能够为临床决策提供资讯的整合解决方案。

明确能够加速药物传输领域数位整合并重塑商业模式的核心技术、监管和经济变革。

互联药物输送格局正经历多重变革，从组件供应链到终端用户行为都受到影响。首先，感测器和嵌入式分析技术的整合正将设备从被动输送装置转变为主动资料来源，从而实现闭合迴路护理和自适应输送策略。同时，临床医生也面临文化上的转变，他们开始依赖持续数据来优化治疗方案并验证其在实际应用中的疗效。

检验了美国宣布的2025年关税政策如何重塑互联药物输送生态系统的供应链、价格压力和产品设计选择。

美国于2025年宣布的关税措施的累积影响，对全球互联药物输送设备的供应链、零件采购和定价策略提出了重大挑战。这些关税推高了电子元件、特殊聚合物和子组件等投入成本，而这些投入成本通常产自受关税影响的地区，迫使製造商重新调整供应商配置，并加快对替代供应商的资格认证。为了应对这些挑战，各公司正在推行区域筹资策略、增加库存缓衝，并协商签订长期合约以稳定采购成本。

细分市场洞察：医疗设备类型、治疗领域、临床环境和通路如何相互作用，从而决定研发重点和商业策略

细分框架的洞察揭示了不同设备类型、药物模式、最终用户和分销管道所面临的独特驱动因素和发展重点。在设备类型方面，此生态系包括输液帮浦、吸入器、注射装置、滴鼻剂和经皮吸收贴片。在输液帮浦领域，肠道餵食帮浦、胰岛素帮浦和病人自控式镇痛帮浦（PCA帮浦）各自有不同的临床介面和数据需求，迫使开发人员根据使用环境和使用者熟悉程度客製化连接解决方案和安全功能。吸入器领域包括干粉吸入器、定量吸入器和雾化器，其不同的驱动机制和气溶胶生成方法对感测器整合和剂量检验技术提出了独特的限制。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将人工智慧驱动的预测演算法整合到胰岛素笔中，以实现个人化剂量调整
  • 推出即时无线监测平台，用于追踪化疗输注依从性
  • 推出一款支援蓝牙功能的智慧吸入器，用于远端撷取患者呼吸数据。
  • 开发基于NFC的药品认证功能以防止假注射剂
  • 扩展的云端基础分析仪表板，供临床医师监控病患用药指标
  • 新兴的智慧型手机应用生态系统实现了与植入式药物泵的双向通讯
  • 将区块链帐本整合到互联药物输送系统中，以增强资料安全性和可追溯性。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按设备类型分類的连网药物传输设备市场

  • 点滴帮浦
    • 肠内泵
    • 胰岛素帮浦
    • PCA泵浦
  • 吸入器
    • 干粉吸入器
    • 定量喷雾吸入器
    • 喷雾器
  • 注射装置
    • 自动注射器
    • 笔式註射器
    • 安全注射器
    • 标准注射器
  • 鼻喷剂
    • 手动喷雾器
    • 雾化喷雾
  • 经皮贴剂
    • 矩阵补丁
    • 水库补丁

9. 依药物类型分類的互联药物输送设备市场

  • 生物製药
  • 生物相似药
  • 小分子药物
  • 疫苗

10. 按最终用户分類的连网药物输送设备市场

  • 门诊治疗中心
  • 诊所
  • 居家医疗
  • 医院

11. 按分销管道分類的连网药物输送设备市场

  • 直销
  • 医院药房
  • 网路药房
  • 零售药房

12. 各地区互联药物传输设备市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

13. 互联药物输送设备市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国互联药物输送设备市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Medtronic plc
    • Becton, Dickinson and Company
    • Baxter International Inc.
    • Roche Holding AG
    • Smiths Group plc
    • Insulet Corporation
    • Tandem Diabetes Care, Inc.
    • Ypsomed Holding AG
    • Novo Nordisk A/S
    • Sanofi SA
Product Code: MRR-3C68ED2D0A4A

The Connected Drug Delivery Devices Market is projected to grow by USD 2,968.19 million at a CAGR of 15.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 966.22 million
Estimated Year [2025] USD 1,110.68 million
Forecast Year [2032] USD 2,968.19 million
CAGR (%) 15.06%

A clear framing of how connectivity, patient-centric design, and regulatory evolution are converging to transform drug delivery devices and clinical pathways

Connected drug delivery devices are redefining the interface between therapeutics, patients, and healthcare systems by embedding sensors, software, and connectivity into traditional delivery platforms. As clinical pathways shift toward decentralized care and value-based outcomes, devices that capture adherence, dose administration, and contextual physiologic data are becoming integral to therapeutic regimens. This transformation is powered by advances in low-power electronics, secure wireless protocols, and a maturing regulatory dialogue around software as a medical device, enabling manufacturers to move beyond standalone hardware toward integrated solutions that inform clinical decision making.

Adoption is being driven by converging pressures: clinicians seek reliable adherence data to optimize treatment, payers demand proof of value, and patients favor convenience and autonomy. As a result, product development teams are rebalancing priorities to include user experience, interoperability with electronic health records, and cybersecurity by design. In parallel, commercialization strategies increasingly emphasize partnerships with digital health platforms, remote monitoring services, and specialty pharmacies. These shifts require manufacturers and stakeholders to rethink R&D pipelines, quality systems, and post-market surveillance to manage both clinical and digital performance.

Identification of the core technological, regulatory, and economic shifts that are accelerating digital integration and redefining commercial models in drug delivery

The landscape for connected drug delivery is being reshaped by several transformative shifts that extend from component supply chains to end-user behavior. First, the integration of sensors and embedded analytics is moving devices from passive dispensers to active data sources that enable closed-loop care and adaptive dosing strategies. This technical evolution is accompanied by a cultural shift among clinicians who increasingly rely on continuous data to fine-tune therapies and to demonstrate real-world effectiveness.

Second, reimbursement and procurement models are beginning to reward outcomes rather than devices alone, encouraging developers to bundle devices with services and digital therapeutics. This economic shift prompts manufacturers to design products that generate measurable value across the patient journey. Third, regulatory frameworks are adapting to software-driven functions, accelerating pathways for connected devices while simultaneously raising expectations for cybersecurity, interoperability, and post-market surveillance. Stakeholders must therefore implement robust lifecycle management processes for software updates and real-world performance monitoring.

Finally, the end-user environment is expanding beyond hospitals into homes and ambulatory settings, requiring devices to be intuitive, safe for non-clinical users, and compatible with diverse distribution channels. Collectively, these forces favor agile development models, strategic alliances with technology providers, and a relentless focus on human-centered design to ensure clinical adoption and long-term engagement.

Examination of how the 2025 United States tariff measures are reshaping supply chains, pricing pressure, and product design choices across connected drug delivery ecosystems

The cumulative impact of the United States tariffs announced in 2025 has introduced material considerations for global supply chains, component sourcing, and pricing strategies for connected drug delivery devices. Tariffs have elevated input costs for electronic components, specialized polymers, and subassemblies that are often manufactured in tariff-affected jurisdictions, prompting manufacturers to reassess supplier footprints and to accelerate qualification of alternative vendors. As firms adapt, many are pursuing regional sourcing strategies, increasing inventory buffers, and negotiating long-term agreements to stabilize procurement costs.

These adjustments have operational effects beyond unit costs. Product development timelines can extend due to new supplier validation, while inventory management requires a higher degree of coordination between procurement, production, and distribution teams. In addition, tariff-induced cost pressure intensifies scrutiny of product architectures, encouraging designers to optimize bill-of-materials and to evaluate modular designs that allow substitution of higher-cost elements. From a strategic perspective, some companies are exploring partial onshoring of assembly or final integration steps to mitigate tariff exposure and to maintain supply continuity for critical clinical accounts.

The tariffs also influence commercial dynamics. Payers and procurement officers may push for price concessions or for outcomes-based contracts that shift financial risk. Consequently, manufacturers face a dual imperative: preserve clinical and digital performance while containing delivered costs through design efficiencies, supplier diversification, and operational resilience. Taken together, these measures aim to protect access and competitiveness in a trade environment that has introduced elevated uncertainty.

Segment-specific intelligence revealing how device subtypes, therapeutic classes, care settings, and distribution pathways jointly determine development priorities and commercial strategies

Insights drawn from the segmentation framework reveal differentiated growth drivers and development priorities across device types, drug modalities, end users, and distribution channels. Based on Device Type, the ecosystem encompasses Infusion Pumps, Inhalers, Injection Devices, Nasal Spray, and Transdermal Patch. Within infusion pumps, Enteral Pumps, Insulin Pumps, and PCA Pumps present distinct clinical interfaces and data requirements, forcing developers to tailor connectivity solutions and safety features according to use setting and user proficiency. The inhaler segment includes Dry Powder Inhalers, Metered Dose Inhalers, and Nebulizers, each imposing unique constraints on sensor integration and dose verification technology due to differences in actuation mechanics and aerosol generation.

Injection Devices are studied across Autoinjectors, Pen Injectors, Safety Syringes, and Standard Syringes, where user ergonomics, dose accuracy, and needle safety mechanisms influence the integration of electronics and adherence-tracking capabilities. Nasal Spray formats subdivide into Manual Spray and Nebulized Spray, a distinction that matters for aerosol characterization, device-to-drug compatibility, and real-world administration patterns. Transdermal Patch modalities, including Matrix Patch and Reservoir Patch, demand attention to skin adhesion, reservoir control, and delivery kinetics, which in turn shape sensor placement and complementing analytics.

Based on Drug Type, the analysis differentiates Biologics, Biosimilars, Small Molecule, and Vaccines, acknowledging that biologic therapies often require cold chain considerations, precision dosing, and compatibility with infusion or injection platforms. Based on End User, insights span Ambulatory Care Centers, Clinics, Home Care, and Hospitals, clarifying how user competencies and care workflows inform training, device ruggedness, and remote support needs. Based on Distribution Channel, the study considers Direct Sales, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, highlighting how channel economics and customer touchpoints affect packaging, documentation, and post-sale digital service models. By aligning product architecture and commercial approaches to these intersecting segments, stakeholders can prioritize investments that address the highest-value combinations of device type, drug modality, care setting, and distribution pathway.

Regional strategic imperatives outlining how regulatory regimes, payer expectations, and health system maturity shape adoption and commercialization across global regions

Regional dynamics exert strong influence on regulatory expectations, reimbursement pathways, and adoption patterns for connected drug delivery devices. In the Americas, healthcare systems are characterized by a mix of private and public payers with high emphasis on evidence of outcomes and cost-effectiveness; this environment incentivizes solutions that demonstrate adherence improvement, reduced hospital utilization, and integration with electronic health records. Manufacturers operating in the Americas often prioritize interoperability standards, commercial models that align with payer contracts, and direct partnerships with integrated delivery networks.

In Europe, Middle East & Africa, heterogeneity across regulatory regimes and procurement processes requires nuanced entry strategies. European regulators and health technology assessment bodies focus on clinical and economic value, driving manufacturers to produce robust real-world evidence and to adapt to centralized and decentralized reimbursement landscapes. The Middle East & Africa region presents opportunities for leapfrogging traditional infrastructure through mobile-enabled solutions, but also demands attention to distribution logistics and localized training programs.

Asia-Pacific encompasses a broad spectrum of maturity from advanced digital health infrastructure to rapidly developing healthcare markets. Adoption here is influenced by government initiatives promoting digital health, a growing emphasis on home-based care, and cost-sensitive procurement policies. Manufacturers targeting Asia-Pacific need to balance global standards with local regulatory compliance, optimize supply chains for regional hubs, and collaborate with local partners to tailor user interfaces, languages, and service models to diverse patient populations.

Strategic company behaviors and competitive approaches demonstrating how platform thinking, focused device excellence, and partnership-led value creation are reshaping competitive positioning

Company strategies in the connected drug delivery domain reveal competing approaches to differentiation, including platform-based ecosystems, focused device excellence, and vertical integration with service offerings. Some firms emphasize modular hardware designs paired with developer-friendly software platforms to attract partners and to create extensible ecosystems for third-party applications. This approach seeks to scale adoption by lowering integration barriers and enabling interoperability with hospital IT and remote monitoring vendors. Other companies concentrate on solving a narrow clinical need exceptionally well, investing heavily in human factors engineering, proprietary sensing technologies, and validated clinical workflows to secure preferred provider status.

A third strategic pathway involves closer alignment with pharmaceutical sponsors and specialty pharmacies, offering co-developed combination products or data-enabled adherence programs that support value-based contracting. Across strategies, leading organizations are strengthening capabilities in cybersecurity, regulatory software lifecycle management, and post-market evidence generation. Competitive advantage increasingly depends on the ability to operationalize data into clinical insights and to present clear value propositions to payers and providers. Partnerships, acquisitions, and collaborative R&D remain common mechanisms to accelerate capability acquisition while spreading development risk across technical and regulatory domains.

Action-oriented recommendations for product leaders, commercial teams, and supply chain executives to accelerate adoption and mitigate operational and regulatory risk

Industry leaders should adopt an integrated set of actions to capture value from connected drug delivery devices while managing operational risks. Begin by embedding user-centered design and clinical workflow integration early in development to ensure devices meet real-world needs and minimize training burdens. Parallel to design work, establish modular architectures that permit component substitution and rapid iteration, which reduces the business impact of supply chain disruptions and tariff-related cost volatility. Invest in rigorous cybersecurity practices and a documented software lifecycle process to meet regulatory expectations and to protect patient safety.

Commercially, pursue bundled value propositions that link device performance to measurable health outcomes and align pricing with payer priorities. Cultivate partnerships with digital health vendors, specialty pharmacies, and hospital IT providers to accelerate interoperability and to create integrated service offerings. Operational resilience requires a diversified supplier base, strategic inventory planning, and contingency sourcing for critical electronic components. Finally, commit to real-world evidence programs and stakeholder education to demonstrate clinical utility and to accelerate adoption across home care, ambulatory, and hospital settings. These combined actions will enhance the ability to deliver clinically meaningful, economically viable connected solutions at scale.

A transparent mixed-methods research approach combining stakeholder interviews, technical assessments, and document analysis to validate practical insights and scenarios

The research methodology is grounded in a mixed-methods approach that combines qualitative interviews, technical analyses, and secondary research to produce validated insights. Primary engagement included structured interviews with clinicians, procurement officers, device engineers, regulatory specialists, and payers to capture practical barriers to adoption, technology preferences, and reimbursement considerations. Technical evaluation assessed device architectures, connectivity options, security frameworks, and integration pathways with electronic health records and remote monitoring platforms to identify implementation constraints and opportunities.

Secondary research complemented primary findings through regulatory guidance documents, standards bodies' publications, patent landscape reviews, and company disclosures to triangulate technology maturity and strategic direction. Data validation employed cross-checks between interview themes and documented evidence, while scenario testing explored implications of supply chain shocks, tariff changes, and regulatory shifts. The methodology emphasizes transparency in assumptions, traceable source citations for factual claims, and iterative validation with subject-matter experts to ensure relevance and practical applicability for decision-makers operating across development, regulatory, and commercial functions.

A concise synthesis of strategic conclusions emphasizing the balance of technical innovation, operational resilience, and evidence-driven commercialization for sustained success

The connected drug delivery landscape presents a combination of technological promise and operational complexity that demands deliberate strategy. Advancements in sensor technologies, wireless connectivity, and analytics create pathways to improve adherence, personalize dosing, and demonstrate outcomes, thereby advancing patient-centric care. At the same time, evolving regulatory expectations, supply chain dynamics, and commercial payment models require manufacturers to align product design, evidence generation, and pricing strategies in a coordinated manner to realize sustained adoption.

Success will depend on the ability to integrate human-centered design with robust digital and cybersecurity practices, to engineer resilient supply chains in the face of trade disruptions, and to develop commercial models that clearly link device-enabled data to clinical and economic value. Organizations that balance technical excellence with pragmatic partnerships and evidence-based commercialization will be best positioned to convert innovation into tangible improvements in patient care and system efficiencies. In this context, timely, focused actions on design, sourcing, and stakeholder alignment will determine which players gain durable advantage.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven predictive algorithms into insulin pens for personalized dosage adjustments
  • 5.2. Adoption of real-time wireless monitoring platforms for chemotherapy infusion adherence tracking
  • 5.3. Implementation of Bluetooth-enabled smart inhalers for remote patient respiratory data collection
  • 5.4. Development of NFC based medication authentication features to prevent counterfeit injectable drugs
  • 5.5. Expansion of cloud-based analytics dashboards for clinicians monitoring patient drug delivery metrics
  • 5.6. Emergence of smartphone app ecosystems enabling two-way communication with implantable drug pumps
  • 5.7. Integration of blockchain ledgers into connected drug delivery to enhance data security and traceability

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Connected Drug Delivery Devices Market, by Device Type

  • 8.1. Infusion Pumps
    • 8.1.1. Enteral Pumps
    • 8.1.2. Insulin Pumps
    • 8.1.3. PCA Pumps
  • 8.2. Inhalers
    • 8.2.1. Dry Powder Inhalers
    • 8.2.2. Metered Dose Inhalers
    • 8.2.3. Nebulizers
  • 8.3. Injection Devices
    • 8.3.1. Autoinjectors
    • 8.3.2. Pen Injectors
    • 8.3.3. Safety Syringes
    • 8.3.4. Standard Syringes
  • 8.4. Nasal Spray
    • 8.4.1. Manual Spray
    • 8.4.2. Nebulized Spray
  • 8.5. Transdermal Patch
    • 8.5.1. Matrix Patch
    • 8.5.2. Reservoir Patch

9. Connected Drug Delivery Devices Market, by Drug Type

  • 9.1. Biologics
  • 9.2. Biosimilars
  • 9.3. Small Molecule
  • 9.4. Vaccines

10. Connected Drug Delivery Devices Market, by End User

  • 10.1. Ambulatory Care Centers
  • 10.2. Clinics
  • 10.3. Home Care
  • 10.4. Hospitals

11. Connected Drug Delivery Devices Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Hospital Pharmacy
  • 11.3. Online Pharmacy
  • 11.4. Retail Pharmacy

12. Connected Drug Delivery Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Connected Drug Delivery Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Connected Drug Delivery Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Medtronic plc
    • 15.3.2. Becton, Dickinson and Company
    • 15.3.3. Baxter International Inc.
    • 15.3.4. Roche Holding AG
    • 15.3.5. Smiths Group plc
    • 15.3.6. Insulet Corporation
    • 15.3.7. Tandem Diabetes Care, Inc.
    • 15.3.8. Ypsomed Holding AG
    • 15.3.9. Novo Nordisk A/S
    • 15.3.10. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CONNECTED DRUG DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CONNECTED DRUG DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CONNECTED DRUG DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ENTERAL PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ENTERAL PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ENTERAL PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ENTERAL PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ENTERAL PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ENTERAL PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INSULIN PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INSULIN PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INSULIN PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INSULIN PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INSULIN PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PCA PUMPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PCA PUMPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PCA PUMPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PCA PUMPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PCA PUMPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PCA PUMPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AUTOINJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY PEN INJECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SAFETY SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY STANDARD SYRINGES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY STANDARD SYRINGES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY STANDARD SYRINGES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY STANDARD SYRINGES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY STANDARD SYRINGES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY STANDARD SYRINGES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MANUAL SPRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MANUAL SPRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MANUAL SPRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MANUAL SPRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MANUAL SPRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MANUAL SPRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZED SPRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZED SPRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZED SPRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZED SPRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZED SPRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NEBULIZED SPRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MATRIX PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MATRIX PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOSIMILARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOSIMILARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOSIMILARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOSIMILARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY BIOSIMILARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INFUSION PUMPS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INHALERS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY INJECTION DEVICES, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY NASAL SPRAY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY TRANSDERMAL PATCH, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CONNECTED DRUG DELIVERY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. EUR